| |
First Allo-HCT |
Second Allo-HCT |
Donor Origin
Related donor
Matched unrelated donor |
19 (86%)
3 (14%) |
18 (82%)
4 (18%) |
Stem Cell Source
Peripheral Blood
Bone marrow
Cord Blood |
11 (50%)
9 (41%)
2 (9%) |
17 (77%)
3 (14%)
2 (9%) |
Conditioning intensity
RIC
Myeloablative |
12 (55%)
10 (45%) |
19 (86%)
3 (14%) |
Conditioning regimen
Flu-Bu-ATG
Flu-TBI
Flu-Cy-TBI
Flu-Cy-TLI
Flu-Bu-TLI
Cy-Bu
Cy-TBI
OTHERS |
8 (36%)
3 (14%)
2 (9%)
0
0
0
5 (23%)
4 (36%) |
4 (18%)
5 (23%)
1
2 (9%)
2 (9%)
1
1
6 (27%) |
GVHD Prophylaxis
CSA
CSA+ MMF
CSA+ MTX
CSA+MMF+MTX |
9 (41%)
5 (22%)
7 (32%)
1 (5%) |
8 (36%)
11 (50%)
3 (14%)
0 |
Disease Status at Allo-HCT
CR
PROGRESSION
MRD |
8 (36%)
11 (50%)
3 (14%) |
9 (41%)
11(50%)
2 (9%) |
Median of CD34+ x 106/kg
Median of CD3+ x106/kg |
4.48 (0.9-9.6)
103 (18-436) |
5.69 (1.36-10.57)
169 (4-628) |
Days with ANC> 500 x 109/l
Days with platelets >50 x 109/l |
|
21 (8-64)
22 (1-64) |
Acute GVHD
grade (II-III)
grade (IV)
Chronic GVHD
Limited
Extensive |
5 (23%)
0
0
|
5 (23%)
0
3 (14%)
2 (9%) |
RIC: Reduced Intensity Regimen; CR: Complete Remission; MRD: Minimal
Residual Disease; Flu: Fludarabine; BU: Busulfan; ATG: Anti-tymoglobuline;
CY: Cyclophosphamide; TBI: Total Body Irradiation; CSA: Cyclosporin A; MMF:
Mycophenolate Mophetyl; MTX: Methotrexate; GVHD: Graft Versus Host Disease